Enanta Pharmaceuticals To Showcase Phase2 Results Of Zelicapavir To Treat RSV In A Webcast

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 to provide topline results from RSVPEDs, a first in paediatrics Phase 2 study of zelicapavir in hospitalised and non-hospitalised children aged between 28 days and 36 months with RSV.

The live webcast can be accessed on the website's “Events & Presentation” section. The archived webcast will be available on Enanta’s website for approximately 30 days following the event.